ECLAXIR:Search for an Association Between CX3CR1 V249I Polymorphism, Preeclampsia and Endothelial Injury
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00190177|
Recruitment Status : Completed
First Posted : September 19, 2005
Last Update Posted : October 18, 2013
|Condition or disease|
It is a case-control multicenter study 185 caucasian pregnant women with preeclampsia and 185 paired controls without preeclampsia will be included.
The frequency of the V249I polymorphism in african black population will be determined by studying 200 subjects (100 cases and 100 controls).
The V249I polymorphism will be identified by PCR followed by enzyme digestion. Endothelial injury will be identified using three assays : von Willebrand factor, soluble VCAM-1 and thrombomodulin plasma levels.
CX3CR1 involvement in preeclampsia would have potential diagnostic and therapeutic consequences.
|Study Type :||Observational|
|Estimated Enrollment :||370 participants|
|Study Start Date :||March 2003|
|Actual Primary Completion Date :||October 2007|
|Actual Study Completion Date :||October 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00190177
|Hôpital Louis Mourier AP-HP|
|Colombes, France, 92701|
|Principal Investigator:||Laurent Mandelbrot, MD-PhD||Assistance Publique - Hôpitaux de Paris|